Kate Rouch Flags Convoluted Drug Development System

Kate Rouch, former CMO of OpenAI and Coinbase, posted that everyone tried their best yet the system for advancing drugs remains too convoluted and risk-averse. She warned the setup should terrify those focused on AI's potential in biology. America leads in basic science, she said, but falls behind in turning discoveries into treatments that save lives. Rouch linked her comments to a New York Times opinion piece stating it is too hard for researchers to launch clinical trials. The posts stress that scientific progress now depends on fixing these hurdles.